Patents by Inventor Tali Gorfine

Tali Gorfine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12239712
    Abstract: The invention relates to pharmaceutical compositions, and more specifically to pharmaceutical compositions comprising at least one fatty acid-bile acid conjugate and at least one thyroid hormone receptor agonist or thyroid hormone mimetic or pharmaceutically acceptable salts thereof, and use of such compositions in methods of treating, stabilizing or lessening the severity or progression of a liver disease including fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and comorbidity ties associated with a liver disease.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: March 4, 2025
    Assignee: GALMED RESEARCH AND DEVELOPMENT LTD
    Inventors: Allen Baharaff, Liat Hayardany-Nissimov, Tali Gorfine
  • Patent number: 11197870
    Abstract: The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), employing the use of 3?-arachidylamido-7?,12?-dihydroxy-5?-cholan-24-oic acid (Aramchol) or a pharmaceutically acceptable salt thereof. In other embodiments, the treatment and inhibition of hepato-fibrotic conditions caused by contact with hepatotoxic chemical substances or by mechanical obstruction is contemplated.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: December 14, 2021
    Assignee: Galmed Research and Development Ltd
    Inventors: Liat Hayardeny-Nissimov, Tali Gorfine, Allen Baharaff, Jose M. Mato de la Paz
  • Publication number: 20210338826
    Abstract: The invention relates to pharmaceutical compositions, and more specifically to pharmaceutical compositions comprising at least one fatty acid-bile acid conjugate and at least one thyroid hormone receptor agonist or thyroid hormone mimetic or pharmaceutically acceptable salts thereof, and use of such compositions in methods of treating, stabilizing or lessening the severity or progression of a liver disease including fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and comorbidity ties associated with a liver disease.
    Type: Application
    Filed: September 3, 2019
    Publication date: November 4, 2021
    Applicant: GALMED RESEARCH AND DEVELOPMENT LTD
    Inventors: ALLEN BAHARAFF, Liat Hayardany-Nissimov, Tali Gorfine
  • Publication number: 20190275061
    Abstract: The invention relates to inhibiting the development of hepatic fibrosis in a human subject afflicted with Non-Alcoholic Fatty Liver Disease and having a fibrosis score of zero comprising administering to the subject greater that 300 mg per day of 3?-arachidylamido-7?, 12?-dihydroxy-5?-cholan-24-oic acid (Aramchol), or a pharmaceutically acceptable salt thereof, thereby inhibiting the development of hepatic fibrosis in said subject.
    Type: Application
    Filed: November 10, 2017
    Publication date: September 12, 2019
    Applicant: GALMED RESEARCH AND DEVELOPMENT LTD
    Inventors: Liat Hayardeny-Nissimov, Tali Gorfine, Allen Baharaff, Jose M. Mato De La Paz
  • Publication number: 20180125862
    Abstract: The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), employing the use of 3?-arachidylamido-7?,12?-dihydroxy-5?-cholan-24-oic acid (Aramchol) or a pharmaceutically acceptable salt thereof. In other embodiments, the treatment and inhibition of hepato-fibrotic conditions caused by contact with hepatotoxic chemical substances or by mechanical obstruction is contemplated.
    Type: Application
    Filed: October 20, 2017
    Publication date: May 10, 2018
    Applicant: Galmed Research and Development Ltd.
    Inventors: Liat Hayardeny-Nissimov, Tali Gorfine, Allen Baharaff, Jose M. Mato de la Paz
  • Publication number: 20180064702
    Abstract: This invention provides a method for treating a human subject afflicted with a progressive form of multiple sclerosis, comprising periodically administering to the human subject an amount of laquinimod effective to treat the human subject. This invention also provides laquinimod for use in treating a human subject afflicted with a progressive form of multiple sclerosis. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a progressive form of multiple sclerosis.
    Type: Application
    Filed: November 13, 2017
    Publication date: March 8, 2018
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Nora Tarcic, Dan Bar-Zohar, Liat Hayardeny, Yossi Gilgun Sherki, Tali Gorfine, Volker Knappertz, Ella Sorani
  • Publication number: 20140235670
    Abstract: This invention provides a method for treating a human subject afflicted with a progressive form of multiple sclerosis, comprising periodically administering to the human subject an amount of laquinimod effective to treat the human subject. This invention also provides laquinimod for use in treating a human subject afflicted with a progressive form of multiple sclerosis. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a progressive form of multiple sclerosis.
    Type: Application
    Filed: February 13, 2014
    Publication date: August 21, 2014
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Nora Tarcic, Dan Bar-Zohar, Liat Hayardeny, Yossi Gilgun Sherki, Tali Gorfine, Volker Knappertz, Ella Sorani